Today at 1:00 p.m. ET Join @PPMD and Capricor for a community webinar discussing positive topline results from the Phase 3 HOPE-3 trial evaluating Deramiocel in DMD. We’ll review the data and discuss how the findings inform ongoing regulatory discussions, including next steps

Today marks a defining moment for the Duchenne community. The U.S. Department of Health and Human Services has added Duchenne muscular dystrophy to the Recommended Uniform Screening Panel, expanding newborn screening nationwide—an important step toward earlier diagnosis and

Capricor is pleased to be participating today in the Oppenheimer Movers in Rare Disease Summit in New York. We will be featured on a rare disease panel and participating in a series of one-on-one meetings to discuss our recent progress and the path ahead. $CAPR #DMD #Deramiocel

Thank you to everyone who joined our conference call and webcast yesterday to review the positive topline results from our pivotal Phase 3 HOPE-3 study of Deramiocel. Interest in the event was exceptionally high, and due to the unusually heavy traffic, our webcast platform

Following this morning’s announcement of positive topline results from our pivotal Phase 3 HOPE-3 clinical study, Capricor will be presenting today at the Piper Sandler 37th Annual Healthcare Conference. We will be featured in a fireside chat starting at 11:30 a.m. ET. To access

Breaking: Capricor is extremely pleased to announce positive topline results from our pivotal Phase 3 HOPE-3 clinical study evaluating Deramiocel in Duchenne muscular dystrophy. HOPE-3 met its primary endpoint and key cardiac secondary endpoint, with all Type 1 error–controlled

On Veterans Day, we pause to honor the courage, sacrifice, and service of our nation’s veterans, and the families who stand beside them. Your commitment inspires us to pursue life-changing science with purpose every day. Thank you for your service. $CAPR #VeteransDay

We just released our third quarter 2025 financial results and provided a corporate update. Click here to read the release: https://t.co/MnuPz5ifZD $CAPR #DMD #deramiocel

We are pleased to announce the publication of new data in the international peer-reviewed journal, Biomedicines describing the mechanism of action and potency assay for our investigational cell therapy, Deramiocel. The publication details how Deramiocel, which is composed of

Capricor will report Q3 financial results after the market close Monday, November 10, 2025, and will host a conference call and webcast at 4:30 p.m. ET that same day. To register for the webcast: https://t.co/HZue1j34ci $CAPR #DMD #deramiocel

We’re proud to share that Capricor Therapeutics has been named one of TIME’s “America’s Growth Leaders 2026,” honoring 500 of the top U.S. public companies recognized for sustained growth and performance. Coming in at #23 of 500, this honor reflects our team’s dedication to

Capricor was pleased to join the Maxim Group 2025 Growth Summit this morning. Our CFO, AJ Bergmann, joined the session: Unlocking Value in Late-Stage/Commercial Rare Disease. Proud to help advance innovation and patient impact across rare disease. Learn more:

Capricor’s CEO, Dr. Linda Marbán will join the most important voices in science and biotech at the STAT Summit taking place this week in Boston. To see the full agenda, click here https://t.co/L86ISGL0zP $CAPR #STATSummit #Biotech #Innovation #FutureOfMedicine #DMD

Capricor is pleased to provide a regulatory update on our Deramiocel program for Duchenne muscular dystrophy (DMD) following our recent Type A meeting with the FDA. We will also be hosting a conference call today at 8:30 AM ET — https://t.co/RaUuIa48r8 #DMD $CAPR #Deramiocel

Capricor is excited to be featured at the Exosome-Based Therapeutics Development Summit taking place this week in Boston, where we will highlight the progress of our exosome platform and its potential to deliver next-generation therapeutics. Learn more: https://t.co/OqIQmrRDtd

Today, on World Duchenne Awareness Day, Capricor stands with patients and families living with DMD. This rare genetic disorder affects thousands worldwide, and together, through awareness and research, we share hope for brighter tomorrows. Capricor remains committed to advancing

We will be featured in a fireside chat today at the Cantor Fitzgerald Global Healthcare Conference scheduled for 10:55 AM ET (7:55 AM PT). Register here for the live webcast: https://t.co/RBCfngXdCR #CantorHealthcare $CAPR #DMD

Capricor will be presenting and participating at two leading industry events this week: the 2025 Wells Fargo Healthcare Conference (Sept. 3–5, Boston) and the Cantor Fitzgerald Global Healthcare Conference (Sept. 3–5, New York). Join our fireside chat at the Wells Fargo